Genmab and AbbVie drug cuts lymphoma progression risk by 51%

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. CSX
6. LRCX
7. LVS
8. SAP
9. SPCX
10. SPY

Go back to Genmab and AbbVie drug cuts lymphoma progression risk by 51%

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell

October 5, 2026 2:49 PM EDT

Company Announcement

COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patientsBased on the topline results, Genmab and AbbVie will engage global regulatory authorities

Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE:... More